Acutaas Chemicals has delivered exceptional returns to investors, with the stock surging 137% over the past year compared to an 8% decline in the benchmark Sensex. According to latest market data, the stock is trading at ₹3,377.35 as of September 11, 2026, representing a 6.74% gain from the previous closing price of ₹3,233.35. The stock has demonstrated remarkable long-term performance, with gains of 383% over two years and 419% over three years as per BSE data. The stock hit a 52-week high of ₹3,735 on 6 July this year, while touching a 52-week low of ₹1,290.05 on 1 October last year. The stock has been trading in the range of ₹3,464.05 to ₹3,224.30 with a volume of 1.04 million shares on both NSE and BSE.
The stock has received strong analyst support with 6 analysts initiating coverage on Acutaas Chemicals. According to the latest analyst data, 2 analysts have given it a strong buy rating and 3 analysts have given it a buy rating, while 1 analyst has given a sell rating. The average broker rating is Buy, reflecting positive sentiment among analysts. The stock's TTM P/E ratio stands at 74.75, which is higher than the sector P/E of 37.29, indicating premium valuation based on recent performance. The market capitalization is ₹28,126.59 crore as of September 10, 2026.
Brokerage firm JM Financial has reinstated a buy rating on Acutaas Chemicals with a target price of ₹3,800 for the next 12 months, as reported by The Hindu BusinessLine. This target price implies an upside of 10% from the current market price of ₹3,377.35. The rating is based on 45 times September 2028E EPS, reflecting JM Financial's positive outlook on the company's growth prospects. The brokerage expects the stock to deliver sustained earnings growth driven by strong fundamentals across multiple business segments.
According to the company's annual report for FY26, Acutaas Chemicals demonstrated robust financial performance with revenue from operations jumping 33% year-on-year to ₹1,339.4 crore. The company's profit after tax (PAT) surged 122% YoY to ₹356.4 crore, while EBITDA jumped 107% YoY to ₹480.4 crore. EBITDA margin increased significantly to 35.9% in FY26 from 23% in FY25, reflecting improved operational efficiency and margin expansion. The company reported a net profit of ₹356.26 crore in 2026 and ₹74.26 crore in the last quarter. The mutual fund shareholding increased to 14.17% by the end of June quarter of FY27, while foreign portfolio investors (FPIs) cumulatively held 21.61% stake.
As reported by The Hindu BusinessLine, JM Financial expects Acutaas Chemicals to deliver strong growth driven by multiple business segments. The brokerage anticipates Daro-V volumes could grow nearly three times over FY26–30E to nearly 160MT by FY30E, supported by expanding Nubeqa patient base following successful clinical trials. The company projects Daro-V revenue of about ₹1,700 crore by FY30E, which would be the key growth driver in the CDMO business. The brokerage anticipates Specialty Chemicals revenue to grow at nearly 45% CAGR from ₹160 crore in FY26 to ₹730 crore by FY30E, driven by higher-value semiconductor chemicals and electrolyte additives. In Pharma Intermediates, four new CDMO molecules are expected to scale up to nearly ₹320 crore by FY30E, while Apixaban's anticipated November 2026 patent expiry is expected to support growth in the legacy pharma business.
According to the shareholding pattern data on BSE, foreign portfolio investors (FPIs) cumulatively held 1,76,90,137 shares, or 21.61% stake in Acutaas Chemicals by the end of June quarter of FY27. Major non-promoter shareholders include Kotak Mahindra Trustee Company holding 28,89,380 shares (3.53% stake) through Kotak Multicap Fund, SBI Healthcare Opportunities Fund with 19,24,544 shares (2.35% stake), Axis Max Life Insurance with 17,93,491 shares (2.19% stake), and Government Pension Fund Global holding 29,01,687 shares (3.54% stake). The company's revenue, EBITDA, and PAT are projected to grow at 28%, 29%, and 28% CAGR respectively over FY26–30E. JM Financial expects an overall revenue/EBITDA/PAT CAGR of 28/29/28% over FY26-30E.
